Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

910 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases.
Peterlin P, Guillaume T, Garnier A, Le Bourgeois A, Mahé B, Dubruille V, Blin N, Gallas P, Touzeau C, Gastinne T, Lok A, Thomare P, Chauvin C, Le Gouill S, Moreau P, Chevallier P. Peterlin P, et al. Among authors: chevallier p. Leuk Res Rep. 2018 Jan 17;9:16-17. doi: 10.1016/j.lrr.2018.01.002. eCollection 2018. Leuk Res Rep. 2018. PMID: 29892542 Free PMC article. No abstract available.
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Roland V, Mahé B, Juge-Morineau N, Dubruille V, Guillaume T, Vigouroux S, Moreau P, Milpied N, Garand R, Avet-Loiseau H, Harousseau JL. Chevallier P, et al. Leuk Res. 2005 Sep;29(9):1003-7. doi: 10.1016/j.leukres.2005.02.005. Epub 2005 Apr 8. Leuk Res. 2005. PMID: 16038726
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL. Chevallier P, et al. J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854573 Clinical Trial.
Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.
Cahu X, Rialland F, Touzeau C, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M. Cahu X, et al. Among authors: chevallier p. Biol Blood Marrow Transplant. 2009 Dec;15(12):1531-7. doi: 10.1016/j.bbmt.2009.07.021. Epub 2009 Sep 25. Biol Blood Marrow Transplant. 2009. PMID: 19896076 Free article.
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M. Malard F, et al. Among authors: chevallier p. Biol Blood Marrow Transplant. 2010 Jan;16(1):28-34. doi: 10.1016/j.bbmt.2009.08.010. Epub 2009 Oct 1. Biol Blood Marrow Transplant. 2010. PMID: 20053329 Free article.
Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.
Clavert A, Le Gouill S, Brissot E, Dubruille V, Mahe B, Gastinne T, Blin N, Chevallier P, Guillaume T, Delaunay J, Ayari S, Saulquin B, Moreau A, Moreau P, Harousseau JL, Milpied N, Mohty M. Clavert A, et al. Among authors: chevallier p. Leuk Lymphoma. 2010 Aug;51(8):1502-8. doi: 10.3109/10428194.2010.497981. Leuk Lymphoma. 2010. PMID: 20583964 Clinical Trial.
910 results